DRD2 多态性与精神分裂症患者代谢综合征的性别特异性关联。
The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia.
机构信息
Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634014 Tomsk, Russia.
Research Institute of Medical Genetics, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634050 Tomsk, Russia.
出版信息
Genes (Basel). 2022 Jul 23;13(8):1312. doi: 10.3390/genes13081312.
BACKGROUND
Metabolic syndrome is widespread in patients with schizophrenia receiving long-term antipsychotic therapy. Dopamine D2 receptors play an important role in mediating both the therapeutic actions of antipsychotics and their side effects. The present study examined the association of two polymorphisms of the DRD2 gene with metabolic syndrome in patients with schizophrenia.
METHODS
We examined 517 patients from several regions of Siberia (Russia) with a clinical diagnosis of schizophrenia. Genotyping of two single nucleotide polymorphisms rs1799732 and rs4436578 of the dopamine D2 receptor gene (DRD2) was performed in a population of 471 patients. The results were analyzed using chi-square tests.
RESULTS
Functional polymorphism rs1799732 of the DRD2 gene is associated with drug-induced metabolic syndrome in women with schizophrenia.
CONCLUSIONS
Our results show that the DRD2 gene may be involved in the pathogenesis of metabolic disorders in patients with schizophrenia. Further analysis of possible genetic markers will allow for personalized treatment with minimal side effects and optimal efficacy. This which seems relevant in light of the recent focus on improving the quality of life and ensuring a high level of social adaptation of patients with schizophrenia.
背景
代谢综合征在接受长期抗精神病药物治疗的精神分裂症患者中广泛存在。多巴胺 D2 受体在介导抗精神病药物的治疗作用及其副作用方面发挥着重要作用。本研究探讨了多巴胺 D2 受体基因的两个多态性与精神分裂症患者代谢综合征的关系。
方法
我们对来自俄罗斯西伯利亚多个地区的 517 例临床诊断为精神分裂症的患者进行了检查。对 471 例患者的多巴胺 D2 受体基因（DRD2）两个单核苷酸多态性 rs1799732 和 rs4436578 的基因分型进行了分析。采用卡方检验进行分析。
结果
DRD2 基因的功能多态性 rs1799732 与女性精神分裂症患者的药物诱导代谢综合征有关。
结论
我们的研究结果表明，DRD2 基因可能参与了精神分裂症患者代谢紊乱的发病机制。进一步分析可能的遗传标记将允许对患者进行个体化治疗，以最小的副作用和最佳的疗效。这在最近关注提高精神分裂症患者的生活质量和确保高水平的社会适应能力的背景下显得尤为重要。
Zotero 插件